Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF1126 + Nivolumab in Advanced HCC
NCT03059147Phase 1Terminated
- Sponsor
- SignalRx Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SF1126 in hepatocellular carcinoma (HCC), sponsored by SignalRx Pharmaceuticals. Primary endpoints: Rate of Dose Limiting Toxicities at 56 days and Maximum Tolerated Dose at 56 days. Started Mar 2017; status: terminated.
02
Drugs
SF1126
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03059147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059147.